$PBYI
PUMA BIOTECHNOLOGY, INC.

2016 Q4 Form 10-Q Financial Statement

#000156459016028617 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q4 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.47M $9.600M $8.810M
YoY Change 71.56% 19.11% 127.65%
% of Gross Profit
Research & Development $56.40M $52.44M $51.92M
YoY Change 7.55% 32.66% 61.79%
% of Gross Profit
Depreciation & Amortization $580.0K $210.0K $200.0K
YoY Change 176.19% 10.53% 25.0%
% of Gross Profit
Operating Expenses $72.87M $62.04M $60.73M
YoY Change 17.46% 30.36% 68.89%
Operating Profit -$60.73M
YoY Change
Interest Expense $200.0K $320.0K $320.0K
YoY Change -37.5% 220.0% 190.91%
% of Operating Profit
Other Income/Expense, Net $10.00K $0.00 -$2.000K
YoY Change -100.0%
Pretax Income -$72.66M -$61.72M -$60.42M
YoY Change 17.73% 29.99% 68.58%
Income Tax
% Of Pretax Income
Net Earnings -$72.66M -$61.72M -$60.42M
YoY Change 17.73% 29.98% 68.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.035M -$1.902M -$1.871M
COMMON SHARES
Basic Shares Outstanding 36.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $229.5M $215.9M $247.8M
YoY Change 6.3% 52.8% 61.01%
Cash & Equivalents $198.8M $31.57M $23.60M
Short-Term Investments $35.00M $184.3M $224.2M
Other Short-Term Assets $7.000M $7.700M $6.900M
YoY Change -9.09% 22.22% 53.33%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $236.5M $223.5M $254.7M
YoY Change 5.79% 49.65% 59.09%
LONG-TERM ASSETS
Property, Plant & Equipment $5.200M $2.383M $2.500M
YoY Change 118.21% 10.48% 31.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.20M $13.90M $14.40M
YoY Change -19.42% 24.11% 44.0%
Total Long-Term Assets $16.30M $16.29M $16.90M
YoY Change 0.04% 21.78% 40.83%
TOTAL ASSETS
Total Short-Term Assets $236.5M $223.5M $254.7M
Total Long-Term Assets $16.30M $16.29M $16.90M
Total Assets $252.8M $239.8M $271.6M
YoY Change 5.4% 47.36% 57.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.00M $17.80M $9.800M
YoY Change 12.34% 18.71% -46.74%
Accrued Expenses $17.40M $14.64M $15.50M
YoY Change 18.86% -50.28% 42.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.50M $32.44M $25.30M
YoY Change 15.59% -27.0% -13.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.500M $1.400M $1.500M
YoY Change 292.86% 7.69% 36.36%
Total Long-Term Liabilities $5.500M $1.400M $1.500M
YoY Change 292.86% 7.69% 36.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.50M $32.44M $25.30M
Total Long-Term Liabilities $5.500M $1.400M $1.500M
Total Liabilities $42.97M $33.84M $26.80M
YoY Change 26.99% -25.98% -12.13%
SHAREHOLDERS EQUITY
Retained Earnings -$796.5M -$520.5M -$458.8M
YoY Change 53.03% 85.09%
Common Stock $1.006B $726.7M
YoY Change 38.49% 82.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $209.8M $206.0M $244.8M
YoY Change
Total Liabilities & Shareholders Equity $252.8M $239.8M $271.6M
YoY Change 5.4% 47.36% 57.82%

Cashflow Statement

Concept 2016 Q4 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$72.66M -$61.72M -$60.42M
YoY Change 17.73% 29.98% 68.56%
Depreciation, Depletion And Amortization $580.0K $210.0K $200.0K
YoY Change 176.19% 10.53% 25.0%
Cash From Operating Activities -$40.96M -$33.03M -$36.87M
YoY Change 24.01% 78.93% 51.6%
INVESTING ACTIVITIES
Capital Expenditures -$550.0K -$60.00K -$150.0K
YoY Change 816.67% -90.48% 25.0%
Acquisitions
YoY Change
Other Investing Activities $21.39M $39.74M -$4.590M
YoY Change -46.18% 73.99% 73.21%
Cash From Investing Activities $20.84M $39.69M -$4.750M
YoY Change -47.49% 78.78% 71.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 162.1M 1.320M 5.370M
YoY Change 12178.79% -79.79%
NET CHANGE
Cash From Operating Activities -40.96M -33.03M -36.87M
Cash From Investing Activities 20.84M 39.69M -4.750M
Cash From Financing Activities 162.1M 1.320M 5.370M
Net Change In Cash 142.0M 7.980M -36.25M
YoY Change 1678.95% -22.3% 33.81%
FREE CASH FLOW
Cash From Operating Activities -$40.96M -$33.03M -$36.87M
Capital Expenditures -$550.0K -$60.00K -$150.0K
Free Cash Flow -$40.41M -$32.97M -$36.72M
YoY Change 22.57% 84.91% 51.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31569000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184320000
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Entity Registrant Name
EntityRegistrantName
PUMA BIOTECHNOLOGY, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001401667
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
PBYI
dei Document Type
DocumentType
10-Q
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4313000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32018869
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36818092
CY2016Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1179000
us-gaap Net Income Loss
NetIncomeLoss
-177565000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-520500000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
680000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
63000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-177502000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-177565000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.55
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
568000
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
179000
us-gaap Share Based Compensation
ShareBasedCompensation
73254000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-368000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1760000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
706000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5214000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-13896000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-183000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-121437000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
943000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3097000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
2997000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
179000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
81794000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
211783000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
209874000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
90457000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
121350000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-125545000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
205133000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
351000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26908000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
351000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
232041000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20972000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14941000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38539000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23598000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include accrued expenses for the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates used to record accrued expenses and to value the stock-based compensation will occur in the near term. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September&#160;30, 2016, were approximately $56.8&nbsp;&nbsp;million. The Company does not believe it is exposed to any significant credit risk due to the quality of the financial instruments in which the money is held. Pursuant to the Company&#8217;s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor&#8217;s Corporation and Moody&#8217;s Investors Service at the time of purchase. </p></div>
CY2016Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
56800000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5542285
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
105.59
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29751000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24956000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
87990000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
73254000
CY2016Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.92
CY2015Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.77
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
2.71
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
2.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
712417
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
416501
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
71800
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5730151
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2736716
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2993435
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
45.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
123.67
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.71
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
169.60
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
96.55
CY2016Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
99.35
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
94.00
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1268000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
79721000
CY2016Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
16048000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
63673000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
89.17
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3572202
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1131402
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
416501
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
73.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
85.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
74.02
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
59.27
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2016Q3 us-gaap Tenant Improvements
TenantImprovements
1200000

Files In Submission

Name View Source Status
0001564590-16-028617-index-headers.html Edgar Link pending
0001564590-16-028617-index.html Edgar Link pending
0001564590-16-028617.txt Edgar Link pending
0001564590-16-028617-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pbyi-10q_20160930.htm Edgar Link pending
pbyi-20160930.xml Edgar Link completed
pbyi-20160930.xsd Edgar Link pending
pbyi-20160930_cal.xml Edgar Link unprocessable
pbyi-20160930_def.xml Edgar Link unprocessable
pbyi-20160930_lab.xml Edgar Link unprocessable
pbyi-20160930_pre.xml Edgar Link unprocessable
pbyi-ex101_197.htm Edgar Link pending
pbyi-ex311_10.htm Edgar Link pending
pbyi-ex312_11.htm Edgar Link pending
pbyi-ex321_6.htm Edgar Link pending
pbyi-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending